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ABSTRACT
Purpose. Trends suggest that cancer spending growth will
accelerate. One method for controlling costs is to examine
whether the benefits of new technologies are worth the ex-
tra costs. However, especially new and emerging technolo-
gies are often more costly, while limited clinical evidence of
superiority is available. In that situation it is often unclear
whether to adopt the new technology now, with the risk of
investing in a suboptimal therapy, or to wait for more evi-
dence, with the risk of withholding patients their optimal
treatment. This trade-off is especially difficult when it is
costly to reverse the decision to adopt a technology, as is the
case for proton therapy. Real options analysis, a technique
originating from financial economics, assists in making this
trade-off.
Methods. We examined whether to adopt proton ther-
apy, as compared to stereotactic body radiotherapy, in the
treatment of inoperable stage I non-small cell lung cancer.
Three options are available: adopt without further re-
search; adopt and undertake a trial; or delay adoption and
undertake a trial. The decision depends on the expected net
gain of each option, calculated by subtracting its total costs
from its expected benefits.
Results. In The Netherlands, adopt and trial was found to
be the preferred option, with an optimal sample size of 200
patients. Increase of treatment costs abroad and costs of re-
versal altered the preferred option.
Conclusion. We have shown that real options analysis
provides a transparent method of weighing the costs and
benefits of adopting and/or further researching new and
expensive technologies. The Oncologist 2011;16:1752–1761
INTRODUCTION
The costs of cancer care have increased substantially in the last
few decades [1, 2]. Recent trends suggest that cancer spending
growth will accelerate, in part because of costly new treat-
ments [3]. As this ongoing increase in costs is causing a serious
financial burden to patients, families, and society at large, sub-
stantial changes in the health care delivery system are needed
to reduce the growth rate of health care spending [2–4]. One
method for controlling health care costs is to examine whether
the benefits of new technologies are worth the extra costs [5].
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Although cost-effectiveness analyses are increasingly used to
assist decision making in cancer care, their results do not al-
ways provide sufficient evidence to make a decision [6, 7].
This is especially the case when a technology is on average
cost-effective but uncertainty exists.
Protons are charged particles that can be used for radiother-
apy. Because of their superior dose distribution, a clinical ben-
efit is expected [8]. Currently, decisions are being made
worldwide whether or not to adopt proton therapy as a standard
treatment, as well as for which indications [9]. However, be-
cause only relatively few studies have investigated the effec-
tiveness of proton therapy, the effects are surrounded with
considerable uncertainty [10–12]. Also, proton therapy is as-
sociated with large investment costs [9, 13]. Recently, Grutters
et al. concluded that proton therapy may be cost-effective in
the treatment of stage I non-small cell lung cancer (NSCLC)
[14]. However, the probability that proton therapy is indeed
more cost-effective than stereotactic body radiotherapy
(SBRT) in this population is only 63%. Hence, the probability
that adopting proton therapy is a wrong decision, which im-
plies that the high investment costs of approximately €95 mil-
lion [13] are not justified, is 37%.
The real decision is whether to adopt proton therapy now,
with the risk of making the wrong decision, or to postpone the
adoption and collect more information in a new trial to reduce
the existing uncertainty, with the risk of giving patients the
suboptimal treatment in the meantime [4, 15]. A potential tech-
nique to assist in making such trade-offs is real options analy-
sis (ROA) [16]. ROA not only provides guidance as to whether
to postpone adoption but also provides guidance as to whether
further research is worthwhile and, if so, what design and sam-
ple size of the trial give the best value for money. In the present
paper we will illustrate how ROA can assist evidence-based
decision making upon emerging promising but uncertain tech-
nologies in cancer care that require implementation costs. We
will apply this state-of-the-art technique, which originates
from financial economics [17, 18], to the case of proton ther-
apy in stage I NSCLC.
METHODS
Background of ROA
The real options approach stems from financial literature [17,
18]. Its advantage is that it does not only consider whether the
benefits of a technology outweigh its costs (as in cost-effec-
tiveness analyses) but also recognizes the option to postpone
adoption of the technology. In health care, when we decide to
delay adoption of a cost-effective but uncertain new technol-
ogy, there is a risk of giving patients suboptimal treatment.
This results in health benefits forgone. On the other hand,
adopting a cost-effective but uncertain new technology in-
volves the risk of wasting a considerable amount of money. In
both cases, uncertainty can be reduced by obtaining additional
knowledge, through performing a trial. ROA can help in as-
sisting the decision of whether to postpone adoption. Addition-
ally, ROA can assist the decision of whether to perform a trial
and, in the case of a trial, in designing the optimal trial, with
regard to sample size, endpoints, and follow-up time.
In health care, ROA is indicated when two key character-
istics are present [19]. First, there should be uncertainty sur-
rounding the decision. When a treatment is cost-effective for
sure, the treatment can be adopted without any doubt because
the probability that the wrong decision is made is zero. Second,
it should be costly or even impossible to reverse the decision to
adopt the technology. This is, for example, the case when im-
plementation costs are very high. In that case, the conse-
quences of making the wrong decision are much higher than
when the decision to adopt can easily be reversed [20, 21]. Be-
cause both characteristics are present in many health care de-
cisions, ROA can potentially be a useful tool in health care
decision making [16, 19, 22].
Calculation of Real Options
ROA can be calculated to support the adoption decision of a
new technology. ROA is performed from a decision-analytic
perspective, which implies that if there would be no costs of
reversal the most cost-effective option should be adopted,
irrespective of whether it is statistically significantly more
cost-effective than its comparator [20]. However, when a
health care technology is cost-effective but it is costly or im-
possible to reverse the decision, there are three options: (a)
adopt without further research; (b) adopt and undertake a trial
(“adopt and trial”); and (c) delay adoption and undertake a trial
(“delay and trial”). The option to delay without further re-
search is not considered because there would be no reason to
delay the adoption of a cost-effective treatment if no further
research is acquired. Which option we choose depends on the
expected net gain of both “adopt and trial” and “delay and
trial” (Fig. 1). If the expected net gains of both adopt and trial
and delay and trial are below zero, this means that the benefits
of trialing do not outweigh its costs, and the preferred option is
to adopt without undertaking a trial. If the expected net gain of
adopt and trial or delay and trial is higher than zero, trialing is
worthwhile, and the option with the highest expected net gain
is preferred (Fig. 1). In case the preferred option includes a trial
(either with adopt or delay), the optimal trial design is the one
that generates the highest expected net gain.
The expected net gain is calculated by subtracting the total
costs from its expected benefits [16]. The total costs of the
adopt and trial and delay and trial options consist of four cost
categories: fixed trial costs, variable trial costs, health benefits
forgone, and extra costs (Table 1). Fixed and variable trial
costs are the costs associated with performing the trial. Health
benefits forgone reflect the consequences of withholding pa-
tients the optimal treatment. They are represented by the ex-
pected net health gain of the technology compared to its
alternative. In monetary terms, this is referred to as the ex-
pected incremental net monetary benefit of the technology. It is
calculated by multiplying the additional effects of the new in-
tervention by the value of one unit of effect, and subtracting the
additional costs. Because new evidence is not yet available,
health benefits forgone are based on the expected incremental
net monetary benefit based on current evidence. Optionally,
extra costs may be relevant such as costs associated with trav-
elling.
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The expected benefits of the adopt and trial and delay and
trial options consist of the value of reduced uncertainty as a
result of performing a trial. This is referred to as the expected
value of sampling information (EVSI) and is calculated using
Bayesian analyses. Specific details on how to calculate EVSI
are described elsewhere [21, 23, 24]. In short, the expected
costs of uncertainty are determined jointly by the probability
that the decision will be wrong and the health benefits forgone
as a result of a wrong decision [20]. A trial will provide addi-
tional evidence and hence will reduce the probability of a
wrong decision. This expected reduction in costs of uncer-
tainty is the value of reduced uncertainty, or EVSI. For each
trial design, for example, for trials with different sample sizes,
the remaining costs of uncertainty are calculated. This requires
an estimate of the outcome of the future trial. However, we do
not know the actual results of a trial in advance. Therefore, we
calculate EVSI for all possible outcomes of a trial design, and
average these to elicit an expected EVSI for this trial design
[24]. Because in the adopt and trial option the technology is
adopted, a reversal of this decision is associated with reversal
costs. Therefore, to calculate the expected benefits of adopt
and trial, the EVSI is reduced by the costs of reversing the de-
cision. However, if the costs of reversal are higher than the
health benefits forgone that are associated with not reversing
the decision, we choose not to reverse the decision. Therefore,
there is only a positive EVSI (because the decision is indeed
reversed) of adopt and trial if the reversal costs are lower than
the health benefits forgone due to suboptimal treatment [16].
Application to Proton Therapy
Because of the theoretical advantage, radiotherapy with pro-
tons has gained increasing attention in the last decade. Approx-
imately 33 institutes around the world are currently operating
facilities, and at least 22 facilities are in the planning stage or
under reconstruction [9]. Many countries, such as Belgium,
The Netherlands, and the United Kingdom, are currently de-
ciding or have recently decided whether or not to invest in pro-
ton facilities [25–27]. Although proton therapy is proven
effective for some indications with a low incidence, for most
indications evidence is lacking [10–12, 28]. This has resulted
in an ongoing lively debate on whether there is sufficient evi-
dence to expand the number of facilities, whether randomized
trials are needed, and if so, how to perform these in the absence
of sufficient proton facilities [9, 29–39].
To decide whether to adopt proton therapy in inoperable
stage I NSCLC, we performed an ROA. This ROA builds upon
a published cost-effectiveness analysis [14]. In this cost-effec-
tiveness analysis, all evidence on costs and effects was synthe-
sized in a decision model, estimating the total costs and effects
(in terms of quality-adjusted life years) per patient over 5
years. Effectiveness of the different treatment options was syn-
thesized using a meta-analysis of observational studies [40].
All evidence that was used as input for the model is listed in the
Appendix. Because the current decisions worldwide are fo-
cused on adopting proton therapy or SBRT as a standard treat-
ment for inoperable stage I NSCLC, for the current analysis we
have restricted the decision problem to these two comparators.
Because both are quickly evolving technologies, we used only
the studies on effectiveness that were from 2004 or later [14].
As a setting we chose The Netherlands, a small country with
16.5 million inhabitants where no proton facility is yet avail-
able.
Because generally all studies on protons and SBRT to date
are observational, and there is a debate about whether it is eth-
Current evidence suggests that the intervention is cost-effective,
but this is uncertain, and the decision to adopt is not easily reversed
Real Options Analysis
Is further research worthwhile?
Expected Net Gain Adopt & Trial
and 
Expected Net Gain Delay & Trial
<0
Should we delay adoption? Adopt the new intervention
NoYes










Delay & Trial 
NoYes
Figure 1. Schematic diagram of the decision to adopt now or wait for more evidence.
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ical to perform randomized studies, we assume that a future
study will be a single-arm study on protons (Table 1). The
study will be performed over a period of 5 years, and 5 years
are needed to build the proton facility. It is assumed that after 5
years the decision can be reconsidered based on the new evi-
dence. From the cost-effectiveness analysis we found that fur-
ther research into the effectiveness of proton therapy in terms
of overall survival was most valuable [14]. Therefore, the end-
point of the proposed study is two-year overall survival. It is
assumed that all consecutive patients are included in the study,
and there is no selection in patients.
Fixed and variable trial costs were assumed to be €50,000
and €1,500 per patient, respectively (Table 1). Health benefits
forgone were based on the initial cost-effectiveness analysis.
This analysis indicated that proton therapy yielded 0.21 extra
quality-adjusted life years, at an additional cost of €10,962
[14]. On the basis of the Dutch value of €80,000 per quality-
adjusted life year [41], this resulted in a net monetary benefit of
€5,970. Extra costs of treatment abroad (€2,900) consist of
travel and lodging costs and were based on a Belgian study
[27].
Uncertainty was handled probabilistically, meaning that
we assigned distributions to all uncertain inputs in the cost-
effectiveness model (online supplemental data) [24]. Parame-
ter values were drawn at random from the assigned
distributions, using Monte Carlo simulation with 10,000 iter-
ations. To calculate the EVSI, the possible outcomes of the fu-
ture study were drawn from a predictive distribution based on
Table 1. Overview of the options to adopt and trial and delay and trial, and their total costs and expected benefits
Adopt and trial Delay and trial Source for input
Time horizon 5 years 5 years
Study design Single-arm study on protons Single-arm study on protons
Protons available? All patients (abroad) Only patients in study
(abroad)
Effective population (Pop) 1,534 1,534 (Annual incidence 53) 
5 years, discounted by 4%
per year 54
Maximum sample size 993 993 (Annual incidence 53) 
3 years (allowing 2 years
follow-up)
Total costs
Fixed trial costs €50,000 €50,000 Expert opinion




€5,970  (Pop  N) Incremental net monetary
benefit for proton therapy
compared with SBRT
(0.21  €80,000 
€10,962) 14
Extra costs of treatment
abroad







EVSI  Pop Based on simulation
results (dependent on
sample size): costs of
uncertainty before trial 
costs of uncertainty after
trial
Reversal costsa €3,096 pp €95 million  0.05,
divided by Pop (1,534)
Expected net gain Expected benefits  total
costs
Expected benefits  total
costs
All calculations are based on the Dutch value of €80,000 per quality-adjusted life year.
aIn the calculation of EVSI, for each simulation round it is determined whether a wrong decision is made (i.e., a negative
incremental net monetary benefit occurs). If so, there are health benefits forgone, which implies there is value in reducing
uncertainty. In the adopt and trial option proton therapy is already adopted. Therefore, the value of reducing uncertainty is
reduced by the reversal costs. However, if the health benefits forgone are lower than the reversal costs, they do not outweigh
the costs of reversal. In that case the decision is not reversed and there is no value in reducing uncertainty.
Abbreviations: EVSI, expected value of sampling information; N, sample size of study; Pop, effective population; pp, per
patient; SBRT, stereotactic body radiotherapy.
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the results of the meta-analysis [40, 42]. For each sample size,
for 200 possible study results the Monte Carlo simulation was
run to calculate the corresponding EVSI. Subsequently, these
200 EVSI estimates were averaged to obtain an expected EVSI
for that sample size. In the adopt and trial option, a facility will
be built. The part of the costs of building the facility that is at-
tributable to the treatment of inoperable stage I NSCLC pa-
tients can be considered reversal costs, as these are wasted
when the decision to adopt proton therapy is reversed. We es-
timated that about 5% of the total costs of €95 million would be
attributable to inoperable stage I NSCLC patients, which re-
sults in €4.75 million, or €3,096 per patient.
All costs and expected gains for the base case analysis are
listed in Table 1. Because the extra costs of treatment abroad
and the reversal costs are uncertain and may differ across ju-
risdictions, we additionally performed sensitivity analyses ex-
cluding and duplicating these costs.
RESULTS
In the base case analysis the expected net gain of adopt and trial
is higher than that of delay and trial for any possible sample
size below 950 patients (Fig. 2). This means that, for the Dutch
setting, adopting proton therapy and undertaking a trial is pre-
ferred over delaying adoption. The expected net gain of adopt
and trial is positive for sample sizes of approximately 70 pa-






















































Figure 2. Expected net gain (ENG) for the options to delay and trial (ENGDT) and adopt and trial (ENGAT) for different sample sizes.
The gray dotted line marks the optimal sample size (highest expected net gain). Abbreviations: ENG, expected net gain; ENGDT, ENG for
the options to delay and trial; ENGAT, ENG for the options to adopt and trial.
Table 2. Overview of the options to adopt and trial and delay and trial, and their total costs and expected benefits for a
sample size of 200 patients
Adopt and trial Delay and trial
Time horizon 5 years 5 years
Trial design Single-arm trial on protons
(N  200)
Single-arm trial on protons
(N  200)
Protons available? All patients (abroad) Only patients in trial
(abroad)
Effective population 1,534 1,534
Total costs €4,799,929 €8,896,929
Fixed trial costs €50,000 €50,000
Variable trial costs €300,000 €300,000
Health benefits forgone due to suboptimal treatment €7,966,929
Extra costs of treatment abroad €4,449,929 €580,000
Expected benefits €6,392,515 €8,152,623
Value of reduced uncertainty after trial (EVSI)a €6,392,515 €8,152,623
Reversal costs accounted for in EVSI
Expected net gain €1,592,586 €744,306
aCalculated using simulation results.
Abbreviation: EVSI, expected value of sampling information.
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sample size of 200 patients, which is thus considered the opti-
mal sample size. This indicates that it is preferred to adopt pro-
ton therapy and undertake a trial with a sample size of 200
patients. A larger sample size may further reduce the uncer-
tainty, but this extra benefit then does not outweigh the extra
costs. In Table 2 the total costs and expected benefits of both
options are listed for this study of N  200.
In a sensitivity analysis, excluding the extra costs of treatment
abroad reduced the total costs of both adopt and trial and delay and
trial and therefore increased the expected net gain of both options.
Adopt and undertake a trial was still the preferred option, with an
optimal sample size of 200 patients (Fig. 3A). Duplicating the
costs of treatment abroad to €5,800 resulted in negative expected
net gains, indicating that the optimal option would be to adopt
proton therapy without undertaking a trial (Fig. 3B). The expected
net gain of adopt and trial became positive when the extra treat-
ment costs abroad were lower than €3,500.
Reducing the costs of reversal to zero had no influence on
the expected net gain of delay and trial. For the adopt and trial
option, it increased the expected benefits, because these were
not reduced by reversal costs. This resulted in an even more
favorable expected net gain, with still an optimal sample size
of 200 patients (Fig. 4A). A duplication of the reversal costs to
€6,191 per patient decreased the expected net gain. In this sen-
sitivity analysis, delay and trial with all patients included in the
study generated the highest expected net gain (Fig. 4B). This
implies that if the reversal costs are €6,191, all patients should
be included in the study.
DISCUSSION
Decisions need to be made on whether to adopt proton therapy
now, with the risk of wasting a considerable amount of money,
or to wait, with the risk of giving patients a suboptimal treat-
ment [15]. In the current paper, we have shown that real op-
tions analysis can assist in making such trade-offs. We found
that for the current Dutch setting it is preferred to adopt proton
therapy in inoperable stage I NSCLC and to undertake a single
arm study with 200 patients. Sensitivity analyses on the costs
of treatment abroad and reversal indicated an even stronger













































































































Figure 3. Results of the sensitivity analysis without (A) and duplicating (B) costs of treatment abroad: expected net gain (ENG) for both
the option to adopt and trial (ENGAT) and the option to delay and trial (ENGDT) for different sample sizes. The gray dotted line marks the
optimal sample size (highest expected net gain). Abbreviations: ENG, expected net gain; ENGDT, ENG for the options to delay and trial;
ENGAT, ENG for the options to adopt and trial.
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if the costs of reversal or costs of treatment abroad increased
substantially.
With the present study we aimed to illustrate the usefulness
of ROA in health care decision making. ROA seems to be es-
pecially useful in the field of oncology, because of the rapid
increase of costly technologies in cancer care. Because the cur-
rent decision problem focuses on proton therapy [9, 25, 26],
and conventional radiotherapy with photons is not likely to be
cost-effective in this population, we limited the analysis to pro-
ton therapy and SBRT [14]. The case of proton therapy com-
pared to stereotactic body radiotherapy for stage I NSCLC is a
timely and relevant case to apply ROA. However, the applica-
tion of ROA also involves a number of challenges. First, the
validity of the ROA approach is dependent on the validity of
the decision model that is used to determine the cost-effective-
ness. Our cost-effectiveness analysis included a synthesis of all
available evidence, which is also presented in the online sup-
plemental data. We therefore have no reason to believe that the
results of the cost-effectiveness analysis, and consequently the
ROA, are not valid. Second, assumptions need to be made to
calculate the expected net gain of adopt and trial and delay and
trial, such as the extra costs of treatment abroad and the rever-
sal costs. In the current study we tried to make the options as
realistic as possible for the Dutch decision problem. Two im-
portant assumptions regarding costs of treatment abroad and
reversal were varied in a sensitivity analysis. This illustrates
how ROA can assist in making decisions, even when uncer-
tainty exists concerning the underlying assumptions. Chang-
ing parameters in a sensitivity analysis informs us on the
robustness of the results. We found that changing the parame-
ters only altered the recommendation to adopt proton therapy
and undertake a single arm study if the reversal costs or costs of
treatment abroad were very high. Third, because inputs such as
the effective population and costs of treatment abroad are
likely to differ between jurisdictions, the results of the current
analysis cannot be directly extrapolated to other jurisdictions.
However, the analysis can be easily adapted to allow for this
extrapolation. Fourth, for the calculation of ROA we need to
predict the outcome of any future trial. Because we cannot













































































































Figure 4. Results of the sensitivity analysis without (A) and duplicating (B) reversal costs: expected net gain (ENG) for both the option
to adopt and trial (ENGAT) and the option to delay and trial (ENGDT) for different sample sizes. The gray dotted line marks the optimal
sample size (highest expected net gain). Abbreviations: ENG, expected net gain; ENGDT, ENG for the options to delay and trial; ENGAT,
ENG for the options to adopt and trial.
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simulate every possible outcome [24]. Depending on the size
of the model and the number of simulations, this can involve a
large computational burden and therefore jeopardize feasibil-
ity of ROA. Fifth, for illustration purposes we needed so sim-
plify some elements in the analysis. For example, we only
calculated the benefits of a trial in terms of additional informa-
tion on 2-year overall survival. As this trial will also yield in-
formation on disease-free survival and toxicity, the actual
benefits of further research may be even larger than we found
in our analysis. Also, we did not compare the value of different
study designs or endpoints. ROA can be easily extended to ex-
amine other trial designs and endpoints and compare their ex-
pected net gains to see which trial design is optimal. Although
this makes the analysis more comprehensive and thereby more
complex, it is possible to use ROA for designing a future trial.
Apart from the ethical issues raised in the current debate [33,
35, 37, 38], the present study shows that observational studies
on proton therapy are also highly worthwhile, even when pro-
ton therapy is already adopted as a standard treatment.
When uncertainty exists about treatments, it is increasingly
common to use access with evidence development schemes,
where a treatment is temporarily adopted and all patients are
monitored for a period of time before a final decision is made
[43]. These schemes are used, for example, for pharmaceuti-
cals, and they hypothesize the possibility of reversal of the
temporary decision without any extra costs. However, when
substantial implementation costs are associated with the adop-
tion of a technology, reversal of a temporary adoption decision
is costly. In oncology, several examples exist of technologies
with high implementation costs, such as magnetic resonance
imaging and positron emission tomography, and very recently
the case of proton therapy [9]. In these cases, “access with ev-
idence development” schemes are not an option, and ROA pro-
vides evidence-based arguments that can be used for decision
making. A real options approach has also been used in a recent
study to examine whether hospitals should invest in positron
emission tomography [44, 45]. From the present study we
found that adopting proton therapy and including all patients in
the trial, which resembles the scheme, was never preferred,
even when there were no reversal costs. This is because beyond
a sample size of 200 patients, monitoring patients is no longer
worthwhile. ROA can therefore be used to guide the design of
these “access with evidence development” schemes.
Additional examples of ROA in health care can be found
[16, 19, 22, 44–46]. However, unlike most of these applica-
tions, our application of ROA is based on Bayesian value of
information analysis, which is quickly expanding in the field of
health services research, particularly in oncology [14, 47–50].
ROA then not only informs about whether we should wait to
implement a technology but also informs on whether to per-
form additional research [16]. Use of ROA therefore requires
knowledge of decision analytic modeling and value of infor-
mation analysis. When adopting a value of information analy-
sis, ROA is a relatively small extra step.
Obviously, ROA will not provide a definite answer
whether to invest in expensive new treatments such as proton
therapy. The current analysis focused on inoperable stage I
NSCLC, which is only a small part of the total patient popula-
tion that could be treated with proton therapy. ROA could also
be used to calculate, for example, whether the adoption of pro-
ton therapy in the treatment of children should be postponed
because of the uncertainty surrounding the probability of sec-
ondary tumors. In this case it is expected that the benefits of
delay would never outweigh the high costs of withholding
these children the optimal treatment for 10–20 years until the
study results become available. Although beyond the scope of
this paper, a ROA based on the total population of cancer pa-
tients potentially eligible for proton therapy would be an inter-
esting topic for further research. This would also assist the
decision of which patients should be prioritized in the case of
limited treatment capacity. Such a comprehensive analysis
could help to decide whether a patient with prostate cancer or
with lung cancer should be prioritized, based on their expected
health benefits. Besides the results of an ROA, other factors,
such as competition or research incentives, may also play an
important role in the decision of whether to invest in proton
therapy. However, ROA does provide evidence-based infor-
mation on whether it would be worthwhile to delay such a de-
cision. Hence, it can be used to make difficult trade-offs such
as the decision of whether to adopt an expensive and uncertain
therapy. This is especially relevant in the case of emerging
therapies where often only limited evidence is available [51].
In addition, it can inform us with regard to the optimal study
design and optimal sample size of a study [23].
There is an ongoing lively debate on whether proton ther-
apy should be adopted in clinical practice and whether further
evidence is needed [9, 29–39]. With such a promising but ex-
pensive technique, it is only natural that these debates exist.
Difficult trade-offs need to be made, with lives of patients pos-
sibly at stake, while evidence is lacking. In this light, Hofmann
recently pointed out that the current debate on proton therapy
contains flawed elements and that these are general flaws par-
ticularly recognized in debates on technology [34]. Indeed, the
current debate tends to overlook the existing evidence on clin-
ical and cost-effectiveness. It is possible that flawed arguments
result in suboptimal cancer treatment, for example, if the tech-
nology is adopted on false premises or if it is rejected on the
basis of an assessment of the quality of the arguments instead
of the technology [34]. Patients deserve the best technology
available, on the basis of the best available evidence and also
on the basis of the best arguments. When analyzing new and
emerging technologies, all risks of harm as well as all possible
benefits need to be taken into account [52]. This needs to be
done in a way that properly acknowledges the uncertainties in
predicting the consequences of adopting the technology. Al-
though it surely is not the only argument in the adoption deci-
sion, we have illustrated that ROA is a useful state-of-the-art
technique that assists in this matter. The use of real options
analysis provides an evidence-based answer to the question of
whether to adopt now or wait for more evidence.
SUPPLEMENTAL DATA
A list of input parameters for the cost-effectiveness model can
be found in supplemental online Table 1A.
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